Press Releases

The Bridge to HOPE trial is being conducted under U.S. Food and Drug Administration (FDA) approved investigational device exemption (IDE) to evaluate the clinical safety and efficacy of static [...]

Steve Schweighardt, founder and former CEO to retire from daily operations but will remain as Chairman of the Board.

Bridge to Life continues to research and develop technology to improve organ preservation and have now added organ perfusion devices including for liver, kidney, lung and heart to our portfolio [...]

Bridge to Life Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced first enrollment and orthotopic liver transplantation in its U.S. [...]

The primary endpoint for the trial is the rate of early allograft dysfunction between treatment groups; additional key endpoints include rates of ischemic cholangiopathy and patient and graft [...]

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the first closing of a growth financing, totaling $56 million, led by [...]

Bridge to Life Chairman & CEO Stevan Schweighardt was interviewed in a feature piece for CEOCFO Magazine. He discusses the challenges of the transplant field and Bridge to Life's current and [...]

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, and Tevosol, Inc., a clinical stage medical device startup, today announced their [...]